Ocugen, the Malvern, Pennsylvania-based biopharmaceutical company, announced on September 1, 2026 that it has dosed the first patient in its global Phase 3 registrational trial of OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. The milestone comes just weeks after the FDA granted OCU410 Regenerative Medicine Advanced Therapy designation on July 29, 2026. Chairman and CEO Dr. Shankar Musunuri called the dosing a defining moment for the program: “Dosing the first patient in our global Phase 3 trial, just weeks after receiving RMAT designation, marks a defining moment for the OCU410 program, and for the millions of people living with geographic atrophy.” Chief Medical Officer Dr. Mohamed Genead described the strength of the program heading into Phase 3: “We are entering a global single Phase 3 with a well-defined program: a dose validated in a randomized, controlled Phase 2 study; an FDA-endorsed primary endpoint measuring the rate of lesion growth; and a secondary endpoint assessing functional vision.” Study investigator Dr. Victor Gonzalez framed the unmet need behind the trial: “Patients with geographic atrophy continue to face irreversible structural and functional loss of the retina, along with limited treatment options.”
A Disease With Few Good Options
Geographic atrophy is an advanced form of dry age-related macular degeneration and the leading cause of irreversible central vision loss in older adults, affecting an estimated 2 to 3 million people across the U.S. and Europe. OCU410 (AAV5-hRORA) is designed as a one-time subretinal gene therapy that delivers the RORA gene to modulate multiple biological pathways implicated in geographic atrophy, including complement overactivation, lipid metabolism, inflammation, and oxidative stress, rather than targeting a single genetic mutation the way many gene therapies do. That “modifier” approach is the same broad strategy behind Ocugen’s other retinal gene therapy candidates, and it’s designed to make OCU410 potentially useful across a wider range of patients than a mutation-specific therapy would reach.
What the Phase 2 Data Actually Showed
The Phase 3 program builds on 12-month data from Ocugen’s ArMaDa Phase 2 study, which enrolled 51 patients. At the medium dose that was carried forward into Phase 3, the therapy produced a statistically significant 31% reduction in lesion growth compared to untreated controls (p<0.05), along with a 27% reduction in ellipsoid zone loss, a separate structural marker of photoreceptor damage. Roughly 20% of treated patients showed no disease progression at all, and 75% saw more than a 30% reduction in lesion growth. Ocugen reported no drug-related serious adverse events and no adverse events of special interest in the Phase 2 study, safety data the company is now looking to confirm at scale.
Inside the Phase 3 Design
The Phase 3 trial, registered as ArMaDa3 (NCT07770828), is a global, multicenter, randomized, controlled study enrolling 237 patients randomized 2:1 to receive OCU410 or remain in an untreated control arm, with sites across the United States, Canada, Europe, and Latin America. The primary endpoint measures the rate of change in lesion area using fundus autofluorescence imaging at baseline and at months 4, 8, and 12, an FDA-endorsed measure of how much the atrophic lesion is growing over time. Ocugen is targeting a Biologics License Application filing in 2028 if the trial reads out successfully.
The Third Ocugen Program to Reach Late-Stage Development
OCU410 isn’t Ocugen’s only modifier gene therapy candidate, and this Phase 3 start places it alongside two other programs the company has already pushed into late-stage trials. OCU400, targeting retinitis pigmentosa, has already completed enrollment in its Phase 3 liMeliGhT study with 140 patients, with topline one-year data expected in the first quarter of 2027 and a rolling BLA submission on track to begin in the third quarter of 2026. OCU410ST, aimed at Stargardt disease, is in its own Phase II/III pivotal GARDian3 study, with interim data expected in the third quarter of 2026 and a BLA filing now targeted for mid-2027. Taken together, the three programs represent Ocugen’s broader bet that a single modifier gene therapy platform can address multiple retinal diseases without needing a separate, mutation-specific therapy for each one.
A Chester County Biotech Advancing a Global Trial
Ocugen remains headquartered in Malvern, Pennsylvania, keeping this Phase 3 milestone rooted in Chester County within Greater Philadelphia’s life sciences corridor even as the trial itself enrolls patients across four continents. For a region known for cell and gene therapy work stretching back to the field’s earliest academic research at the University of Pennsylvania, Ocugen’s push toward a potential 2028 BLA filing for a genuinely novel, mutation-agnostic approach to a disease with few existing treatments is a notable marker of how far that regional expertise has traveled into late-stage, global clinical development.
